Results 191 to 200 of about 65,254 (248)

Optimal dosing for vascular anomalies paediatric patients with population pharmacokinetic model of sirolimus

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aim Sirolimus is currently used off‐label for paediatric patients with vascular anomalies. However, the optimal dosage regimen for paediatric patients remains controversial. This study aimed to determine the optimal dosing regimen of sirolimus in these patients using a population pharmacokinetic (PK) model.
Seongmee Jeong, Jungryul Kim, Woojin Jung, Jiyeon Jeon, Hyeongjun Jo, Kyoung‐Bin Ryu, Ja‐Young Hong, Kwan Soo Kim, Seongjun Yang, Hee Young Ju, Hwi‐yeol Yun, Jung‐woo Chae, Keon Hee Yoo, Soyoung Lee   +13 more
wiley   +1 more source

Global uptake of GLP-1 receptor agonists in obese, non-diabetic patients with cardiovascular disease. [PDF]

Eur Heart J Qual Care Clin Outcomes
Chi KY, Pollanen S, Hu JR, Lee PL, Mangalesh S, Ezenna C, Joseph M, Krishna MM, Lin YS, Romero Acero LM, Chang Y, Damluji AA, Nanna MG.   +12 more
europepmc   +1 more source

Infusion rate adjustment in enzyme replacement therapy with pabinafusp alfa for mucopolysaccharidosis II

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aims Enzyme replacement therapy (ERT) for mucopolysaccharidosis II (MPS II) requires long‐term, weekly intravenous infusions often lasting over 3 h each time, which can burden paediatric patients and caregivers and negatively affect their quality of life and treatment compliance.
Kimitoshi Nakamura, Norio Sakai, Hideaki Hirai, Naoko Takasao, Ryo Ibaraki, Tatsuyoshi Yamamoto, Yuji Sato   +6 more
wiley   +1 more source

Yoga and Tai chi: a cross-cultural comparative study of health benefits, cultural sustainability, and global public health implications. [PDF]

Front Public Health
Zhou H, Bojarczuk A, Shen G, Chen S, Zhong K, Chen J, Zhong W.   +6 more
europepmc   +1 more source

Cost‐effectiveness of DPYD genotyping prior to fluoropyrimidine‐based treatment for colorectal cancer in Wales

British Journal of Clinical Pharmacology, EarlyView.
Abstract Background Regulatory guidance in the United Kingdom advises DPYD genotyping prior to fluoropyrimidine‐based treatment. This economic evaluation estimated the costs and outcomes associated with DPYD screening prior to prescribing fluoropyrimidines for colorectal cancer in Wales and also considers additional variants to those included in ...
Catrin O. Plumpton, Sian M. Morgan, Richard A. Adams, Samantha Cox, Angharad A. Rudkin, Megan Fealey, Craig Barrington, Michelle D. Wood, Dyfrig A. Hughes   +8 more
wiley   +1 more source

Quantifying the AI readiness gap: An international, multidisciplinary assessment of artificial intelligence literacy in the radiation oncology community. [PDF]

Clin Transl Radiat Oncol
Malone C, Callens D, Forde E, Leech M, Cardenas C, Gooding MJ, Ryan S, Thirion P, Fitzpatrick C, O'Donovan T, Carver A, Giron IH, Browne DP, Rogerson C, McClean B, Heijmen BJM, Hanna GG, Nicholson J.   +17 more
europepmc   +1 more source

Evaluation of a pantoprazole and 4‐desmethylpantoprazole‐sulfate metabolic ratio as a novel CYP2C19 phenotyping method

British Journal of Clinical Pharmacology, EarlyView.
Aims CYP2C19 is one of the most important pharmacogenes, and its activity is highly variable due to factors such as genetics or drug–drug interactions. Due to the lack of an appropriate endogenous CYP2C19 biomarker, surrogate methods to assess its activity are warranted.
Julian Peter Müller, Vladimir N. Belov, Sabrina Yamoune, Bob Miller, Mohammed Hasoumi, Jolanta Tupiec, Thea Laurentius, L. Cornelius Bollheimer, Julia C. Stingl, Katja S. Just   +9 more
wiley   +1 more source

Evaluating a digital serious game for learning medical terminology in a randomized controlled trial. [PDF]

NPJ Digit Med
Kimiafar K, Mousavi Baigi SF, Sarbaz M, Sobhani-Rad D, Darroudi A, Marouzi P, Tabatabaei SM, Khadem Rezaeian M, Sohrabi-Far M, Esmaeili M.   +9 more
europepmc   +1 more source

Exploring individualized crovalimab dosing in PNH through in silico modelling: Potential for improved convenience and cost efficiency

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aim Paroxysmal nocturnal haemoglobinuria (PNH) is a rare, acquired haematopoietic stem cell disorder. Crovalimab, a complement C5‐inhibitor, is approved for PNH and can be self‐administered subcutaneously every 4 weeks, offering a more convenient route than intravenous C5‐inhibitors.
Mendy ter Avest, Simon E. Koele, Nicole C. A. J. van de Kar, Saskia M. C. Langemeijer, Rob ter Heine   +4 more
wiley   +1 more source

Camouflaging and autism: Conceptualisation and methodological issues. [PDF]

Autism
Arnold WM, Bitsika V, Sharpley CF.
europepmc   +1 more source